#nablabio

🚀 Big News in AI & Biotech! 🤖💊

The world of drug discovery is changing fast — and this partnership proves it.

U.S.-based biotech company Nabla Bio has announced an expanded collaboration with Japan’s Takeda Pharmaceutical, taking AI-driven drug design to the next level.

Under this new multi-year deal, Nabla Bio will receive tens of millions upfront, with the potential to earn over $1 billion in milestone payments. The two companies are teaming up to create AI-designed protein-based therapeutics that target hard-to-treat diseases, including next-generation multi-specific biologics.

What’s powering this innovation? Nabla’s proprietary AI platform, Joint Atomic Model (JAM) — think “ChatGPT for molecules.” JAM can design antibodies from scratch, optimizing for precise molecular interactions, and can move from digital design to lab testing in just 3–4 weeks — one of the fastest cycles in the industry.

As more pharma leaders integrate AI into R&D, this partnership marks a major milestone for faster, smarter, and more efficient drug development.

💡 The future of medicine is intelligent — and it’s happening now.